Circulating microRNAs in serum of nivolumab-treated lung cancer patients
Latest Information Update: 17 Feb 2019
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 17 Feb 2019 New trial record